![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
Glucagonoma - 50 Studies Found
Withdrawn |
: Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors :
|
Active, not recruiting |
: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer :
|
Recruiting |
: Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors :
|
Terminated |
: Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery :
|
Active, not recruiting |
: Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors :
|
Active, not recruiting |
: Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors :
|
Active, not recruiting |
: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors :
|
Completed |
: Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors :
|
Terminated |
: Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors :
|
Completed |
: Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors :
|